About
About Auris Medical Holding Ltd
Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.
Visit company website
5 years, 5 months ago
Auris Medical Holding Ltd is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 91.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 111.0.
Finally, its free cash flow fell by 2.4% to $-2M since the same quarter in the previous year.
Based on the above factors, Auris Medical Holding Ltd gets an overall score of 2/5.